A practical reference on reference standard: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-02. Anything still debated is marked as such rather than presented as settled.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
=== Down syndrome === Adults with Down syndrome had accumulation of amyloid in association with evidence of Alzheimer's disease, including declines in cognitive functioning, memory, fine motor movements, executive functioning, and visuospatial skills.
Acquired C1 esterase inhibitor deficiency Acute urticaria Adrenergic urticaria Anaphylaxis Aquagenic urticaria Autoimmune urticaria Cholinergic urticaria Chronic urticaria (ordinary urticaria) Cold urticaria Dermatographism (dermographism) Episodic angioedema with eosinophilia (Gleich's syndrome) Exercise urticaria (exercise-induced urticaria) Galvanic urticaria Heat urticaria Hereditary angioedema (Quincke's edema) Localized heat contact urticaria Mast cell-independent urticaria Physical urticaria Primary cold contact urticaria Pressure urticaria (delayed pressure urticaria) Reflex cold urticaria Schnitzler syndrome Secondary cold contact urticaria Solar urticaria Systemic capillary leak syndrome Urticarial allergic eruption Urticaria-like follicular mucinosis Vibratory angioedema
In June 2023, The U.S. Food and Drug Administration (FDA) authorized for marketing Eroxon, an over-the-counter non-medicated hydro-alcoholic gel indicated for treatment of erectile dysfunction. In the clinical trial, erection was achieved by most men within ten minutes after applying the gel. The gel is manufactured by Futura Medical, a British medical company. The gel is regulated as a medical device and not as a drug, because its mode of action is a physical one and it doesn't have an active pharmaceutical ingredient. Eroxon is the first topical ED treatment sold over the counter in the United States. The gel had been on sale in Europe under a CE mark since 2023, and it reached American shops in October 2024. As of 2026, the gel is sold in the United States, United Kingdom, Europe, and several countries in Latin America and the Middle East.
Sources: en.wikipedia.org
Reincarnation is a paramount tenet in the Druze faith. There is an eternal duality of the body and the soul and it is impossible for the soul to exist without the body. Therefore, reincarnations occur instantly at one's death. While in the Hindu and Buddhist belief system a soul can be transmitted to any living creature, in the Druze belief system this is not possible and a human soul will only transfer to a human body. Furthermore, souls cannot be divided into different or separate parts and the number of souls existing is finite. A male Druze can be reincarnated only as another male Druze and a female Druze only as another female Druze. A Druze cannot be reincarnated in the body of a non-Druze. The cycle of rebirth is continuous and the only way to escape is through a complete soul purification. When this occurs, the soul is united with the Cosmic Mind and achieves the ultimate goal. In the major Christian denominations, the concept of reincarnation is not present and it is nowhere explicitly referred to in the Bible. However, the impossibility of a second earthly death is stated by 1 Peter 3:18–20, where it affirms that the messiah, Jesus of Nazareth, died once forever for the sins of all the human kind. Matthew 14:1–2 mentions that king Herod Antipas took Jesus to be a risen John the Baptist, when introducing the story of John's execution at Herod's orders. Some Christian theologians interpret certain Biblical passages as referring to reincarnation.
==== Office of Regulatory Affairs ==== The Office of Regulatory Affairs is considered the agency's "eyes and ears", conducting the vast majority of the FDA's work in the field. Its employees, known as Consumer Safety Officers, or more commonly known simply as investigators, inspect production, warehousing facilities, investigate complaints, illnesses, or outbreaks, and review documentation in the case of medical devices, drugs, biological products, and other items where it may be difficult to conduct a physical examination or take a physical sample of the product. The Office of Regulatory Affairs is divided into five regions, which are further divided into 20 districts. The districts are based roughly on the geographic divisions of the federal court system. Each district comprises a main district office and a number of Resident Posts, which are FDA remote offices that serve a particular geographic area. ORA also includes the Agency's network of regulatory laboratories, which analyze any physical samples taken. Though samples are usually food-related, some laboratories are equipped to analyze drugs, cosmetics, and radiation-emitting devices.
Membrane-introduction mass spectrometry (MIMS) is a method of introducing analytes into the mass spectrometer's vacuum chamber via a semi-permeable membrane. Usually a thin, gas-permeable, hydrophobic membrane is used, for example polydimethylsiloxane. Samples can be almost any fluid including water, air or sometimes even solvents. The great advantage of the method of sample introduction is its simplicity. MIMS can be used to measure a variety of analytes in real-time, with little or no sample preparation. MIMS is most useful for the measurement of small, non-polar molecules, since molecules of this type have a greater affinity for the membrane material than the sample. The advantage of this method is that complex samples that cannot diffuse through the membrane are not incorporated into the mass spectroscopic measurements, highlighting the simplicity of only analyzing (small) molecules of interest.
Primary treatments: use physical methods such as flotation, screening, and sedimentation to remove oil and grease and other suspended solids. Secondary treatments: use biological and physicochemical means. Biological treatments use microorganisms to metabolise the organic polluting matter into energy and biomass. "These microorganisms can be aerobic or anaerobic. The most used aerobic processes are activated sludge system, aerated lagoons, trickling filters or bacterial beds and the rotating biological contractors. During anaerobic digestion, microorganisms break down organic matter without oxygen, producing biogas, mainly methane and carbon dioxide, and a nutrient-rich residue called digestate. The digestion of protein- and fat-rich fish waste can be slowed by the accumulation of ammonia and fatty acids. Mixing fish waste with other organic materials can improve process stability, although the results depend on the mixture and operating conditions. In the physicochemical treatments, also called coagulation-flocculation, a chemical substance is added to the effluent to reduce the surface charges responsible for particle repulsions in a colloidal suspension, thus reducing the forces that keep its particles apart. This reduction in charge causes flocculation (agglomeration) and particles of larger sizes are settled and clarified effluent is obtained. The sludge produced by primary and secondary treatments is further processed in digesting tanks through anaerobic processes or sprayed over land as a fertilizer.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.